The German biotechnology firm, backed by Microsoft Corp founder and
billionaire Bill Gates, sold 13.33 million shares at $16 apiece, the
top end of its indicated price range of between $14 and $16 per
share.
CureVac is researching how to use messenger RNA to treat a series of
diseases, including the coronavirus. It is an experimental approach
that has also been adopted by some of its peers, including Moderna
Inc and BioNTech SE.
Bank of America, Jefferies, and Credit Suisse are lead underwriters
on the IPO. CureVac shares are due to start trading on Nasdaq on
Friday under the symbol 'CVAC'.
(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Shounak
Dasgupta)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
|